Abstract:BACKGROUND: For the recent prevention of chemotherapy-induced nausea and vomiting (CINV) in children aged 6 months and older, neurokinin-1(NK-1) receptor antagonists were suggested. However, there is little information available on how to select NK-1 receptor antagonists for pediatric patients, such as aprepitant and fosaprepitant. METHODS: Children between the ages of 2 and 12 who were scheduled to undergo chemotherapy that was either mildly or strongly emetic were randomly randomized to receive fosaprepitant (arm-A) or aprepitant (arm-B). For the children in arm-A, ondansetron and dexamethasone were administered intravenously, followed by a fosaprepitant infusion. The identical medications were administered to children selected for arm-B, with the exception that aprepitant was used instead of fosaprepitant. Dexamethasone and ondansetron were continuously administered for 48 hours following the conclusion of treatment. The proportion of patients who experienced a complete response (CR), which is defined as no vomiting, no retching, and no need for rescue medication, during the acute phase (0-24 hours after the last dose of chemotherapy) was administered, was the study's main end point. The percentage of patients who achieved a CR overall and within the delayed period (24-120 hours) following the last chemotherapy treatment were considered secondary end goals. RESULTS : A total of 108 patients were examined (55 in the fosaprepitant arm and 53 in the aprepitant arm). In the acute phase (95% vs 79%, P =0.018, P<0.05), delayed phase (71% vs 66%, P =0.586), and overall phase (69% vs 57%, P =0.179), CR rates were greater in the fosaprepitant arm than in the aprepitant arm. Additionally, there is no difference between the aprepitant arm (11%) and the fosaprepitant arm (7%) in terms of the desire for rescue anti-emetics. CONCLUSIONS: Adding fosaprepitant to ondansetron and dexamethasone is more beneficial than adding aprepitant for preventing CINV in the acute phase. Fosaprepitant and aprepitant, however, do not significantly differ from one another for prevention throughout the delayed and overall phases. This study was approved by IRB of Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine (No. SCMCIRB-K2020120-2), and it was prospectively registered with the ClinicalTrials.gov on April 22, 2021 (reference number: NCT04873284 ).

PCN10 ORAL H2RA for Taxane Hypersensitivity Prevention: A Pharmacokinetic-Guided Decision

Exclusion of ranitidine from premedication regimen during paclitaxel treatment: A retrospective single-center analysis

Quantification of paclitaxel in rat plasma by LC-MS/MS and pharmacokinetics of paclitaxel thermosensi-tive liposomes in rats

Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT

Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy

Prodrug Strategy to Address Impaired Oral Absorption of a Weakly Basic TYK2 Inhibitor Caused by a Gastric Acid-Reducing Agent

Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study

Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience

Low‐dose or Standard‐dose Proton Pump Inhibitors for Maintenance Therapy of Gastro‐oesophageal Reflux Disease: a Cost‐effectiveness Analysis

Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies

Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis

Efficacy and Safety of Fosaprepitant in the Prevention of Nausea and Vomiting Following Highly Emetogenic Chemotherapy in Chinese People: A Randomized, Double-Blind, Phase III Study.

Aprepitant versus a single dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: A randomized, parallel-group, phase III trial

Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis

Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial

Premedication Practices and Incidence of Infusion-Related Reactions in Patients Receiving Amphotec: Data from the Proact-Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability

Double Action Alginate-Antacid Tablets Provide Effective and Safe Relief of Acid Reflux and Dyspepsia Symptoms in Chinese Patients With Gastro-Esophageal Reflux Disease (GERD)

Using QI to develop a sustainable method for titrating taxane infusions to reduce hypersensitivity reactions

An Alternative Paclitaxel Self-Emulsifying Microemulsion Formulation: Preparation, Pharmacokinetic Profile, and Hypersensitivity Evaluation.

An alternative paclitaxel self-emulsifying microemulsion formulation: Preparation, pharmacokinetic profile, and evaluation